Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has scheduled its first quarter 2025 financial results announcement and corporate update for Thursday, May 1, 2025. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. Interested participants can access the webcast through the company's website, where a recorded version will be available shortly after the event and remain accessible for approximately 90 days.

News Market Reaction – TARS

+0.06%

+0.06% Session move

In the trading session that priced this news, TARS gained 0.06%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When will Tarsus Pharmaceuticals (TARS) release Q1 2025 earnings?

Tarsus Pharmaceuticals will release its Q1 2025 earnings on Thursday, May 1, 2025, via a live webcast at 1:30 p.m. PT / 4:30 p.m. ET.

How can investors access the TARS Q1 2025 earnings call?

Investors can access the webcast through the company's website. A recorded version will be available shortly after the event.

How long will the TARS Q1 2025 earnings call recording be available?

The recorded version of the earnings call will be archived on the company's website for approximately 90 days.

What will be discussed in the TARS May 1, 2025 webcast?

The webcast will cover Tarsus Pharmaceuticals' first quarter 2025 financial results and provide a corporate update.